GAITHERSBURG, Md.--(BUSINESS WIRE)--Jan. 30, 2007--Emergent
BioSolutions Inc. (NYSE:EBS) today announced that it will present at
the BIO CEO & Investor Conference 2007 in New York. Fuad El-Hibri,
president, chief executive officer and chairman of the board of
directors of Emergent BioSolutions will provide a company overview and
outline future growth opportunities at 1:30 pm EST, Tuesday, February
13, 2007 at the Waldorf Astoria in New York, NY.
A webcast of the presentation will be available both live and by
replay. To access both the live and archived webcast, please go to
www.emergentbiosolutions.com, click on the "Investors" link and
proceed to the "Webcasts & Presentations" section. The archived replay
will be available 24 hours after the live presentation and will be
accessible for 30 days.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused
on the development, manufacture and commercialization of
immunobiotics, such as vaccines and therapeutics that induce or assist
the body's immune system to prevent or treat disease. The company's
biodefense business is focused on developing and commercializing
immunobiotics for use against biological agents that are potential
weapons of bioterrorism. The company's commercial business is focused
on developing immunobiotics for use against infectious diseases with
significant unmet or underserved medical needs. More information on
the company is available at www.emergentbiosolutions.com.
CONTACT: Emergent BioSolutions Inc.
Robert G. Burrows, 301-795-1877
SOURCE: Emergent BioSolutions Inc.